Advertisement


Shrinivas Rathod, MD, on NSCLC: Quality-of-Life Outcomes From an IAEA Trial

2017 ASTRO Annual Meeting

Advertisement

Shrinivas Rathod, MD, of the University of Manitoba, discusses phase III study results on optimization of treatment of advanced non–small cell lung cancer using radiation therapy and chemotherapy (Abstract 223).



Related Videos

Survivorship

James E. Bates, MD, on Pediatric Cancer Survivors: New Findings on Late Effects

James E. Bates, MD, of the University of Florida, discusses a volumetric dose-effect analysis of late cardiotoxicity, results from the Childhood Cancer Survivor Study (Abstract 4).

Prostate Cancer

Tamim Niazi, MDCM, on Prostate Cancer: Results From a Trial on Dose Escalation

Tamim Niazi, MDCM, of McGill University, discusses phase III study findings on hypofractionated, dose-escalation radiation therapy for high-risk adenocarcinoma of the prostate (Abstract 281).

Gynecologic Cancers

Marcus E. Randall, MD, on Endometrial Cancer: Results From a Gynecology Oncology Group Study

Marcus E. Randall, MD, of the University of Kentucky, discusses phase III study findings on pelvic radiation therapy vs vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy in patients with high-risk, early stage endometrial cancer (Abstract LBA1).

Prostate Cancer

Juanita Crook, MD, on Prostate Cancer: Results From an NRG/RTOG Brachytherapy Trial

Juanita Crook, MD, of the University of British Columbia, discusses late toxicity findings on transperineal ultrasound–guided brachytherapy for locally recurrent prostate cancer after external-beam radiation therapy (Abstract 1).

Prostate Cancer
Kidney Cancer

Gerard Morton, MD, on GU Highlights: Expert Perspective

Gerard Morton, MD, of Sunnybrook Odette Cancer Centre, summarizes a session that included discussion of late toxicities of radiotherapy for locally recurrent prostate cancer; using chemotherapy instead of radiation in early-stage seminoma; radiotherapy vs surgery plus radiotherapy in Gleason score 9–10 prostate cancer; and an analysis of the IROCK study on kidney cancer (Abstracts 1, 1089, 282, 330).

Advertisement

Advertisement




Advertisement